The evolving therapeutic revolution in adult acute lymphoblastic leukemia


Por: Kantarjian, H, Jain, N, Litzow, MR, Luger, SM, Papayannidis, C, Ribera, JM, Short, NJ, Chifotides, HT and Jabbour, E

Publicada: 15 may 2025
Resumen:
The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia-like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions, like the BCR::ABL1 tyrosine kinase inhibitors, as well as novel agents that target CD19 and CD22: the CD22 antibody-drug conjugate inotuzumab ozogamicin, the bispecific CD3/CD19 T-cell engager antibody blinatumomab, and CD19 chimeric antigen receptor T-cell therapies. These combinations have improved the long-term survival rates in B-cell ALL to 70%, and in Philadelphia chromosome-positive ALL to 80%-90%. The desired goals are to achieve cure rates comparable to those in pediatric ALL and to reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.

Filiaciones:
Kantarjian, H:
 Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

Jain, N:
 Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

Litzow, MR:
 Mayo Clin, Div Hematol, Rochester, MN USA

Luger, SM:
 Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA USA

Papayannidis, C:
 IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

:
 Catalan Inst Oncol, Clin Hematol Dept, Barcelona, Spain

 Catalan Inst Oncol, Stem Cell Transplantat Unit, Barcelona, Spain

Short, NJ:
 Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

Chifotides, HT:
 Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

Jabbour, E:
 Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA
ISSN: 10970142





Cancer
Editorial
John Wiley & Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Review
Volumen: 131 Número: 10
Páginas:
WOS Id: 001492102600013
ID de PubMed: 40323723
imagen Green Submitted

MÉTRICAS